scholarly journals Metronomic oral vinorelbine doublet chemotherapy with carboplatin in treatment of advanced lung cancer: a feasibility and safety study

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 673
Author(s):  
Maria Kandi ◽  
Peter Meldgaard ◽  
Marianne Marquard Knap
Keyword(s):  
Lung Cancer ◽  
Standard Dose ◽  
Advanced Lung Cancer ◽  
Continuous Exposure ◽  
Open Label ◽  
Oral Vinorelbine ◽  
Female Ratio ◽  
Male Female Ratio ◽  
Doublet Chemotherapy ◽  
Metronomic Vinorelbine

Background: Non-small cell lung cancer (NSCLC) is globally one of the most common forms of cancer. Palliative treatment is a delicate balance against toxicity and survival. Using small frequent doses of chemotherapy, metronomic regimens have been hypothesized to maintain or even improve efficacy while achieving a lower treatment-related toxicity. The mechanism is thought to result from a more continuous exposure of the tumour cells to the drugs. Treating NSCLC, this study addresses the feasibility and tolerability of carboplatin in combination with 12 weeks of daily metronomic vinorelbine. Method: Patients were included over a period of ten months. All patients had biopsy-verified incurable NSCLC and were candidates for first line chemotherapy (PD-L1<50% and no targetable mutations). This open label, non-randomized prospective safety and feasibility study was investigator initiated. Patients received up-to four cycles of standard dose carboplatin AUC 5 every third week in combination with 12 weeks of metronomic oral daily Navelbine® (20/30 mg). Patients were evaluated by CT scans after end of treatment and then every 8 weeks (+/- 1 week) until progression. Results: A total of 20 patients were included. Male/female-ratio was 4/16. Age ranged from 49-83 with a median of 70.5 years. Majority had adenocarcinoma (95%). Two patients withdrew their consent within a week. 18 patients were included in safety analysis. 13 received all four cycles. Grade 1/2 toxicity was frequently seen and included fatigue 13 (72%), diarrhoea 13 (72%), constipation/congestion 13 (72%). Grade 3 toxicities were dyspnoea 2 (11%), nausea 3 (17%) and fatigue 3 (17%). Two (11%) had grade 4 toxicity with neutropenic fever, both recovered. No grade 5 toxicity was detected. Conclusion: In treatment of NSCLC this study is the first addressing the regimen of carboplatin in combination with daily metronomic vinorelbine. We conclude that doublet chemotherapy with daily vinorelbine is safe and feasible.

scholarly journals Subdural to subgaleal shunts: alternative treatment in infants with nonaccidental traumatic brain injury?

2015 ◽  
Vol 15 (3) ◽  
pp. 306-309 ◽  
Author(s):  
Thomas Blauwblomme ◽  
Federico Di Rocco ◽  
Marie Bourgeois ◽  
Kevin Beccaria ◽  
Giovanna Paternoster ◽  
...  
Keyword(s):  
Postoperative Infection ◽  
Open Label ◽  
Intraoperative Complication ◽  
Female Ratio ◽  
Efficient Treatment ◽  
Open Label Study ◽  
Male Female Ratio ◽  
Subdural Drain ◽  
Median Width ◽  
The Ideal

OBJECT The ideal treatment for subdural hematomas (SDHs) in infants remains debated. The aim of this study was to analyze the safety and efficiency of subduro-subgaleal drainage in SDH. METHODS The authors conducted a single-center open-label study between August 2011 and May 2012. Data were prospectively collected in a database and retrospectively analyzed. RESULTS Eighteen patients (male/female ratio 1.25) with a median age of 5 months were surgically treated. All had preoperative symptoms of intracranial hypertension or seizures. The SDH was bilateral in 16 cases, with a median width of 12 mm. Success of the procedure was noted in 14 of the 18 patients. There was no intraoperative complication or postoperative infection. Drainage failure was attributable to suboptimal positioning of the subdural drain in 2 cases and to migration in 1 case. CONCLUSIONS Subduro-subgaleal drainage is an efficient treatment that could be proposed as an alternative to external subdural drainage or subduroperitoneal drainage.

U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer

2019 ◽  
Vol 36 (1) ◽  
pp. 20-28
Author(s):  
Tatiane Bomfim Ribeiro ◽  
Adalton Ribeiro ◽  
Luíza de Oliveira Rodrigues ◽  
Guilherme Harada ◽  
Moacyr Roberto Cuce Nobre
Keyword(s):  
Lung Cancer ◽  
Drug Administration ◽  
Kinase Inhibitor ◽  
Food And Drug Administration ◽  
Drug Approval ◽  
New Drugs ◽  
Cytotoxic Agents ◽  
Advanced Lung Cancer ◽  
Open Label ◽  
Cancer Data

ObjectiveThis paper aims to describe the clinical and regulatory aspects of new drugs and indications that were approved for lung, breast, prostate, and colorectal cancer, from 2016 to 2018, in order to provide health technology assessment trends in oncology.MethodsData were collected from the US Food and Drug Administration (FDA) online database for new medications and indications approved for the above-mentioned types of cancer. Data regarding clinical study characteristics and regulatory information were collected.ResultsFrom 2016 to 2018, 53 percent of the FDA approvals of new drugs and indications for the most incident cancers were for oral protein kinase inhibitor monotherapy for advanced lung cancer. Since 2018, four drugs were approved as tumor-agnostic therapies. A biomarker was included in 72 percent of indications, and 58 percent of approvals were for targeted therapies, potentially heralding an end to research into conventional cytotoxic agents. A special designation for faster approval was granted in 78 percent of new approvals. The majority of the studies were open label randomized controlled trials (RCTs) (44 percent), followed by blind RCTs, single-arm clinical trials, and cohort studies. Only 14 percent of studies used overall survival as the primary end point; the vast majority used surrogate end points, and did not use patient-important outcomes. Three biosimilars were approved in the period.ConclusionAdvanced lung cancer therapy, mainly targeted drugs, accounted for 53 percent of approvals. Special designations for faster approval were used in 78 percent of FDA approvals, and four drugs were approved for tumor-agnostic treatment—a new form of approval.

scholarly journals Distribution of Cancer Patients at National Institute of Cancer Research and Hospital in 2006

1970 ◽  
Vol 37 (1) ◽  
pp. 2-5 ◽  
Author(s):  
Md Habibullah Talukder ◽  
Suraiya Jabeen ◽  
Md Johirul Islam ◽  
Syed Md Akram Hussain
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Cancer Research ◽  
Cancer Patients ◽  
Lymphoid Tissue ◽  
Pediatric Patients ◽  
Clinical Evidence ◽  
Oesophageal Carcinoma ◽  
Female Ratio ◽  
Male Female Ratio

A study on 6492 new cancer patients was done at National Institute of Cancer Research & Hospital (NICRH), Mohakhali, Dhaka from January 2006 to December 2006. Histopathologically confirmed cancer patients; patients having radiological or clinical evidence of malignancy were included in the study. Majority of the patients were from Dhaka division (47.8%) and next from Chittagong division (22.5%). There were 3824 male and 2668 female patients in the study. The male female ratio was 1.4:1.The majority of cancer occurred in middle and old age. In adult male Lung cancer ranked the top (909, 24.1%) followed by cancer of lymph node and lymphatic (264, 7.0%), Laryngeal carcinoma (247, 6.5%) and Oesophageal Carcinoma (199, 5.3%). Breast cancer (24.48) was the major malignancy amongst adult female (633, 23.3%) followed by that of the cervix (583, 21.4%), Lung (153, 5.6%) and Oral cavity (116, 4.3%). In pediatric patients malignancy of lymphatics and lymphoid tissue led the tally while in geriatric group Lung cancer found to be more prevalent. DOI: 10.3329/bmj.v37i1.3599 Bangladesh Medical Journal 37(1) 2008 2-5

High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial

2021 ◽  
Vol 22 (3) ◽  
pp. 321-331 ◽  
Author(s):  
Bjørn Henning Grønberg ◽  
Kristin Toftaker Killingberg ◽  
Øystein Fløtten ◽  
Odd Terje Brustugun ◽  
Kjersti Hornslien ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Standard Dose ◽  
Small Cell ◽  
High Dose ◽  
Phase 2 ◽  
Thoracic Radiotherapy ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 2 Trial
Sign in / Sign up

Export Citation Format

Share Document